Interest in the field of antibody-drug conjugates (ADCs) has grown exponentially over the past decade. As the product pipeline grows, there is increasing need for robust chemistries which allow selective and efficient functionalization of the antibody cores for introduction of appropriate linkers and spacer groups. Under conventional bioconjugation conditions, product heterogeneity often results, and the drug-to-antibody ratios (DAR) are inconsistent. Based on our experience in protein derivatization, we have investigated the potential for continuous-flow microreactor technology to expedite and facilitate such processes. We demonstrate its potential using reagent proteins and the chimeric monoclonal antibody infliximab (Remicade™).
Introduction
Antibody-drug conjugates (ADCs) are a unique and rapidly emerging class of targeted therapeutics. The use of a monoclonal antibody to direct a cytotoxin to a specific cellular target (e.g., the surface antigens of a tumor cell) reduces the potential for bystander toxicity and offers the potential to require lower therapeutic doses of the drug. Central to this strategy is the need for a covalent linker which preserves the fidelity of the conjugate until it reaches target [1] .
Simplistic in its approach (oft considered the embodiment of Ehrlich's "magic bullet" concept), a number of challenging obstacles need to be addressed in the choice of linker and the chemical coupling reactions in order that consistency required for regulatory approval is attained. Given the enormous potential of these agents, considerable progress has been made and several ADCs have already been approved by the FDA. Adcetris™ (brentuximab vedotin), developed by Seattle Genetics, was introduced in 2011 as a treatment for relapsed Hodgkin's lymphoma or systemic anaplastic large cell lymphoma [2] . More recently, Kadcyla™ (ado-trastuzumab emtansine) was developed by Genentech and approved in 2013 to treat HER2+ metastatic breast cancer [3] . The antibody, also known as Herceptin, binds the HER2 receptor on the surface of a breast cancer tumor cell, and upon cell uptake, lysosomal degradation releases the toxin mertansine to induce cell death.
Developing and conjugating ADCs come with many challenges that are being extensively investigated by academic and biopharmaceutical industry research groups [4] . ADCs are often difficult to purify and characterize and are composed as a distribution of linkages, depending on the method of conjugation [5] . In the case of conjugating the drug via cysteine residues generated from breaking disulfide bonds, drug tagging comes in multiples of two, as seen in Adcetris™, where the average is four drugs per antibody. When conjugating through a lysine residue, the drug binds the free amine, as in Kadcyla™, which contains a wide distribution and results in an average of 3.4 drugs per antibody. Therefore, under conventional means, the drug-to-antibody ratio (DAR) can prove difficult to control effectively.
In order to investigate this concept further, we report our preliminary findings of protein conjugation experiments using continuous-flow microreactor technology. Flow chemistry has been employed in a diverse range of settings, from both research and process chemistry standpoints. For this solutionbased approach, reagents are pumped through a glass microreactor chip, which takes advantage of the high surface area to volume ratio to afford superior heating and mixing over conventional reaction setups. As a result, synthetic processes have been shown to proceed not only in a faster manner, but they often result in fewer byproducts and cleaner product profiles under flow conditions [6].
Results and Discussion
2.1. Proof of Principle with N-Succinimidyl Fluorobenzoate. As a first proof-of-principle study, N-succinimidyl-4-fluorobenzoate (FSB, 1) was conjugated to specimen protein standards using conventional and flow-mediated conditions. Reagent 1 was selected as in 18 F-labelled form it has applications in positron emission tomography (PET) imaging [7] allowing real-time biodistribution of conjugates to be monitored in vivo. The standards utilized included serum albumins, insulin, interferon, and myoglobin and were carried out under various reaction conditions probing time, temperature, and the role of base triethylamine (TEA) (Scheme 1 and Table 1 ).
After purification, the number of FSB tags per protein was determined by subsequent analysis using liquid chromatographymass spectrometry (LC-MS) with electrospray ionization (see Supporting Information). Due to the slightly basic nature of the buffer (pH = 8), the impact of base was negligible and, in some cases, impeded conjugation. Temperature clearly plays a role, with a fine balance between chemical conversion and product degradation needing to be navigated. Based on prior experience working with sensitive substrates, the impact of microwave acceleration was probed and, as expected, had a beneficial impact (entries 5 and 15). Spurred by this, preliminary reactions were investigated using flow conditions and found to produce derivatized product within 1 min at ambient temperature both in the case of myoglobin and the reagent protein bovine serum albumin (BSA) (entries 17-18). The findings are noteworthy and offer a potentially useful means for in vivo imaging of protein biodistribution via the 18 F analog of 1 as the method (including workup and purification) is compatible with the t 1/2 of the isotope (~120 min).
2.2. Comparative Tagging Studies Using Fluorescein Isothiocyanate. With a flow method for protein derivatization revealed, we selected the reagent protein BSA as a standard from which to explore the conjugation parameters in greater depth. Fluorescein isothiocyanate (FITC), a commonly used fluorescent probe, was chosen for the conjugations, which were conducted under both conventional and flow conditions. FITC, which couples to BSA via lysine conjugation to the isothiocyanate was selected due to its high fluorescence intensity, allowing accurate reaction monitoring via spectrophotometric methods (Scheme 2).
Reaction time, temperature, and the number of equivalents of FITC were varied under both conventional and flow conditions. For the flow experiments, a Chemtrix® Labtrix® Start instrument was configured with the Chemtrix® #3223 microreactor, with two inlets, one quench, and one outlet. Temperatures from 4°C to 37°C were studied in an effort to minimize denaturation ( Table 2) . After conjugation and purification, the average number of FITC tags was determined using ultraviolet-visible (UV-vis) spectrophotometry and application of the Beer-Lambert law.
Overall, use of flow conditions significantly accelerated protein tagging when comparing equivalent ratios of FITC to BSA under conventional conditions. For example, entry 27 shows a three-fold increase in tagging from conventional to flow, while simultaneously decreasing the reaction time from 720 min to 300 s. Increasing temperature slightly increased the degree of tagging in general. Increasing the residence time for flow reactions did not uniformly result in an increase in tagging, while as expected, increasing the equivalents of FITC had a pronounced impact. From this, one can conclude that degree of conjugation is less dependent on time, but rather on the ratio of tag to protein in solution. In the case of reagent-grade proteins and tags, this is of little consequence; however, in the case of antibody drug conjugations, where complex toxins are employed, this has obvious ramifications.
2.3. Conjugation of FSB to Infliximab (Remicade™) under Conventional and Flow Conditions. With the utility of the flow methodology established, we wished to confirm its application Scheme 1. FSB conjugation to proof of principle protein standards 
All reactions carried out with 3 equiv. FSB. a Reactions were carried out under microwave irradiation. for the derivatization of a therapeutic antibody. The chimeric antibody infliximab (Remicade™) was chosen for this purpose, and conjugation was assessed under both conventional and flow reaction conditions, as detailed in Scheme 3.
Conjugation reactions under conventional conditions were accomplished by dissolving infliximab (1 mg/mL) in phosphate buffered saline (PBS) buffer, followed by the addition of a solution of FSB in dimethyl sulfoxide (DMSO). Upon completion of the reaction, the samples were purified, and the number of FSB tags per protein was determined by reduction of the intact mAb to the heavy chain (HC) and light chain (LC) and subsequent analysis using LC-MS with electrospray ionization (Table 3) . At ambient temperature, the increase in molar equivalents of FSB plays a larger role than increased reaction time (entries 1-4), with 10 equivalents extending tagging to the HC as well as the LC. Increasing the temperature to 37°C (3 equivalents tag) results in tagging of the HC as well (entry 5).
Gratifyingly, repeating the reactions under optimized flow conditions (reactor setup as in Scheme 3) resulted in controlled derivatization within 1 min (Table 4) . Specifically, using 10 equivalents at ambient temperature or 5 equivalents at 37°C resulted in 1  0  2  2 5  3  3  1  0  3  2 5  1 0  1  3  2  4  2 5  1 0  3  3  3  5  3 7  3  1  1  2 tagging of two FSB groups within 60 s. Also noteworthy is the fact that additional residence time did not impact outcome, and no derivatization of the heavy chain of the mAb was detected under the reaction/workup conditions employed. This implies a degree of selectivity, and specificity is afforded in the process, which bodes well for future studies on the use of flow for ADC syntheses.
Conclusions
Based on these initial experiments, we believe that continuousflow microreactor technology is a viable option for exploring antibody-drug conjugations. The unparalleled efficiency of mixing and heating within these systems has demonstrated their ability to expedite reaction times and increase tagging with BSA and infliximab. We anticipate that the technology will be of use in reagent-limited conjugations and in cases where the structural integrity of the chimera can be compromised under the conditions of bioconjugation. We are actively investigating the locus of tagging of this and other ADCs and also the potential to effect in-line purification of the conjugates to allow direct interface to LC-MS systems.
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